Abstract
Treatment of patients with advanced renal cell carcinoma (RCC) has changed dramatically with the advent of targeted therapeutics. Temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), has proven beneficial in the treatment of advanced RCC with poor prognosis. The rationale for mTOR inhibitors in treatment of RCC, the pharmacokinetics and toxicities of temsirolimus, landmark clinical trials of temsirolimus in advanced RCC, and the indications for its use in the treatment of RCC are reviewed here. The status of temsirolimus in the rapidly evolving therapeutic landscape of advanced RCC is also discussed.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Renal Cell / complications
-
Carcinoma, Renal Cell / drug therapy*
-
Clinical Trials as Topic
-
Drug Interactions
-
Humans
-
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
-
Liver Failure / complications
-
Liver Failure / physiopathology
-
Liver Neoplasms / complications
-
Liver Neoplasms / drug therapy*
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Renal Insufficiency / complications
-
Renal Insufficiency / physiopathology
-
Sirolimus / adverse effects
-
Sirolimus / analogs & derivatives*
-
Sirolimus / pharmacokinetics
-
Sirolimus / pharmacology
-
Sirolimus / therapeutic use
-
TOR Serine-Threonine Kinases
Substances
-
Antineoplastic Agents
-
Intracellular Signaling Peptides and Proteins
-
temsirolimus
-
MTOR protein, human
-
Protein Serine-Threonine Kinases
-
TOR Serine-Threonine Kinases
-
Sirolimus